Pfizer recently announced its fourth quarter and full-year financial results for the fiscal year 2014. According to the report, Pfizer’s fourth-quarter revenue was $13.18 billion, down 3% from $13.558 billion in the same period last year; net profit was $1.228 billion, down 52% from $2.568 billion in the same period last year.
During the quarter, Pfizer's net profit was $1.228 billion, down 52% from $2.568 billion in the same period last year; earnings per share were $0.19, down 51% from $0.39 in the same period last year. Excluding certain one-time items, Pfizer's adjusted net profit for the fourth quarter was $3.441 billion, down 7% from $3.686 billion in the same period last year; adjusted earnings per share were $0.54, down from $0.56 in the same period last year. %, this performance exceeded analysts' previous expectations. Financial information provider FactSet survey shows that analysts on average expect Pfizer's adjusted earnings per share for the fourth quarter to be $0.53.
Pfizer's fourth-quarter revenue was $13.18 billion, down 3% from $13.558 billion in the same period last year. This performance also exceeded analysts' expectations. According to the FactSet survey, analysts on average expected Pfizer's fourth-quarter revenue to be $12.9 billion.
By business unit, Pfizer's globally established pharmaceutical division (GEP) revenue for the fourth quarter was $6.407 billion, down 11% from $7.16 billion in the same period last year; global innovations in the pharmaceutical sector (GIP) was $3.748 billion, Last year's 3.645 billion US dollars increased by 3%; global vaccine sector revenue was 1.318 billion US dollars, an increase of 18% over the same period last year of 1.118 billion US dollars; consumer health sector revenue was 953 million US dollars, compared with 943 million US dollars in the same period last year 1%; global cancer sector revenue was $609 million, an increase of 10% from $565 million in the same period last year.
Throughout FY14, Pfizer's revenue was $46.605 billion, down 4% from FY13.84 billion in FY2013; net profit was $9.135 billion, down 58% from $12.303 billion in FY2013; earnings per share were 1.42 US dollars, down 55% from the 3.19 US dollars in fiscal 2013. Pfizer's adjusted net profit for the fiscal year 2014 was $14.530 billion, down 5% from $15.288 billion in fiscal 2013; adjusted earnings per share were $2.26, a 2% increase from $22.2 in fiscal 2013.
Pfizer expects the company's revenue to be between $44.5 billion and $46.5 billion in FY2015, compared to the FactSet survey, which analysts expect on average to Pfizer's fiscal 2015 revenue of $47.4 billion. Pfizer also expects FY15 earnings per share to be between $1.37 and $1.57, and adjusted earnings per share will be between $2.00 and $2.10, compared to the FactSet survey, which analysts expect on average for Pfizer The annual earnings per share will be $2.16.
After the earnings report, Pfizer's share price fell by nearly 2% in the pre-market trading of the New York market, and then rebounded to more than 1%. Pfizer shares rose 13% in the three months to Monday's close, which outperformed the Dow Jones Industrial Average, which rose 5.1% over the same period.
Candy consumption trend is developing towards nutrition, health and functional field in worldwide. Therefore, we develop a series of healthy sugar-free chewing gum for sub-health people, including refreshing energy gum, collagen gum, weight losing gum, probiotic gum, GABA sleep gum, VC skin-care gum, hangover cure gum, nicotine gum, oral-care gum, etc., those can not only protect the health of teeth but also supplement the nutrients needed.
Functional Chewing Gum,Swallowing Gum,Sugarless Chewing Gum,Natural Chewing Gum
Soar Biotech Co.,Ltd , https://www.xylitgum.com